THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM

被引：0
|
作者：
Sands, Bruce E.
Taub, Pam R.
Feagan, Brian G.
Armuzzi, Alessandro
Friedman, Gary S.
Moscariello, Michele
Lawendy, Nervin
Pedersen, Ronald D.
Chan, Gary
Nduaka, Chudy I.
Quirk, Daniel
Salese, Leonardo
Su, Chinyu
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1750
引用
收藏
页码：S380 / S380
页数：1
相关论文
共 50 条
  • [1] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - UPDATED RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
    Sands, Bruce E.
    Taub, Pam R.
    Feagan, Brian G.
    Armuzzi, Alessandro
    Damiao, Aderson O.
    Lawendy, Nervin
    Solano, Gaston
    Kwok, Kenneth
    Woolcott, John
    Salese, Leonardo
    Su, Chinyu
    GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1190
  • [2] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAM
    Vermeire, Severine
    Armuzzi, Alessandro
    Kwok, Kenneth K.
    Lawendy, Nerrvin
    Woolcott, John
    Salese, Leonardo
    Su, Chinyu
    Hudesman, David
    GASTROENTEROLOGY, 2021, 160 (06) : S353 - S353
  • [3] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Friedman, G. S.
    Moscariello, M.
    Lawendy, N.
    Pedersen, R. D.
    Chan, G.
    Nduaka, C. I.
    Quirk, D.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S23 - S23
  • [4] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Damiao, A. O.
    Lawendy, N.
    Solano, G.
    Kwok, K.
    Woolcott, J.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S557 - S558
  • [5] Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program
    Winthrop, Kevin L.
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Salese, Leonardo
    Thorpe, Andrew J.
    Lawendy, Nervin
    Chan, Gary
    Pedersen, Ronald D.
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S427 - S429
  • [6] Tofacitinib for the Treatment of Ulcerative Colitis: An Updated Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program
    Winthrop, Kevin L.
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Hart, Ailsa
    Alharbi, Othman R.
    Salese, Leonardo
    Lawendy, Nervin
    Mundayat, Rajiv
    Su, Chinyu
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S323 - S323
  • [7] Pharmacology and safety of tofacitinib in ulcerative colitis
    Lopez-Sanroman, Antonio
    Esplugues, Juan, V
    Domenech, Eugeni
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2021, 44 (01): : 39 - 48
  • [8] Tofacitinib for ulcerative colitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (07): : 475 - 475
  • [9] Tofacitinib in ulcerative colitis
    Archer, Thomas P.
    Moran, Gordon W.
    Ghosh, Subrata
    IMMUNOTHERAPY, 2016, 8 (05) : 495 - 502
  • [10] Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Gecse, Krisztina
    Kinnucan, Jami A.
    Connelly, Susan B.
    Salese, Leonardo
    Su, Chinyu
    Kwok, Kenneth K.
    Woolcott, John C.
    Armuzzi, Alessandro
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (05) : 744 - 751
12345